inflammatory diseases Archives -

An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the

Novel drug to tackle inflammatory diseases begins trial

https://pharmaphorum.com/news/novel-drug-to-tackle-inflammatory-diseases-begins-trial/

Market Access/ News/ News

NICE backs Novartis’ Cosentyx for underdiagnosed back condition

Phil Taylor axial spondyloarthritis, Cosentyx, HEOR, inflammatory diseases, NICE, Novartis 0 Comment

NICE has extended the range of indications that Novartis’ Cosentyx can be prescribed for by the NHS in

NICE backs Novartis’ Cosentyx for underdiagnosed back condition

https://pharmaphorum.com/news/nice-backs-novartis-cosentyx-for-underdiagnosed-back-condition/

Market Access/ News/ News

Alvotech files lawsuit challenging AbbVie’s Humira patent thicket

Richard Staines AbbVie, Alvotech, biosimilars, Humira, inflammatory diseases, patent 0 Comment

Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira

Alvotech files lawsuit challenging AbbVie’s Humira patent thicket

https://pharmaphorum.com/news/alvotech-files-lawsuit-challenging-abbvies-humira-patent-thicket/

News/ News/ R&D

Sanofi licences in potential oral IL-17 drug from UK’s C4X Discovery

Richard Staines Biotech, C4XD, inflammatory diseases, psoriasis, Sanofi 0 Comment

Sanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal

Sanofi licences in potential oral IL-17 drug from UK’s C4X Discovery

https://pharmaphorum.com/news/sanofi-licences-in-potential-oral-il-17-drug-from-uks-c4x-discovery/

News/ News/ R&D

Amgen buys inflammatory diseases drug firm Rodeo for up to $721m

Richard Staines Amgen, inflammatory diseases, M&A, R&D, Rodeo Therapeutics 0 Comment

Amgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its

Amgen buys inflammatory diseases drug firm Rodeo for up to $721m

https://pharmaphorum.com/news/acquisitive-amgen-buys-inflammatory-diseases-drug-firm-rodeo-for-up-to-721m/

News/ News/ R&D

Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trial

Richard Staines Eli Lilly, inflammatory diseases, mirikizumab, ulcerative colitis 0 Comment

A phase 3 trial of Lilly’s inflammatory diseases challenger mirikizumab in ulcerative colitis has met its target –

Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trial

https://pharmaphorum.com/news/lillys-mirikuzumab-hits-target-in-phase-3-ulcerative-colitis-trial/

Market Access/ News/ News

BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitis

Phil Taylor Bristol-Myers Squibb, fda, inflammatory diseases, ulcerative colitis, Zeposia 0 Comment

Bristol-Myers Squibb’s commercial hopes for new multiple sclerosis drug Zeposia have yet to bear fruit thanks to the

BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitis

https://pharmaphorum.com/news/bms-eyes-may-fda-verdict-for-ms-drug-zeposia-in-ulcerative-colitis/

News/ News/ R&D

GSK suffers another R&D setback, axing ulcerative colitis drug trial

Richard Staines GlaxoSmithKline, Immutep, inflammatory diseases, ulcerative colitis 0 Comment

GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in

GSK suffers another R&D setback, axing ulcerative colitis drug trial

https://pharmaphorum.com/news/gsk-suffers-another-rd-setback-axing-ulcerative-colitis-drug-trial/

News/ News/ R&D

AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi

Richard Staines AbbVie, Humira, inflammatory diseases, psoriatic arthritis, Skyrizi 0 Comment

AbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms

AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi

https://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/

Trending

inflammatory diseases

Login